On March 28, 2025 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, reported two poster presentations at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper)’s European Lung Cancer Congress 2025 (ELCC 2025) (Press release, VolitionRX, MAR 28, 2025, View Source [SID1234651593]). The studies demonstrate how Volition’s Nu.Q H3K27Me3 biomarker, when combined with circulating tumor DNA, may improve the prognostic value for overall survival and could help inform treatment decisions in Non Small Cell Lung Cancer (NSCLC); and how Volition’s Nu.Q H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ELCC 2025 is taking place in Paris, France, from March 26-29, 2025.
ELCC 2025 Poster Session Details
Poster Session and Table: #282P
Title: "Early detection of stage I/II NSCLC by immunoassay of crosslinked plasma cell fee nucleosomes"
Presenter: Jake Micallef, PhD, MBA, Volition Chief Scientific Officer
Date and Time: Friday, March 28, 2025, 1:00PM – 1:45PM (CET)
Poster Session and Table: #395P
Title: "H3K27Me3-nucleosome is a strong prognostic biomarker in non-small cell lung cancer (NSCLC): Interim results from the analysis of up to 832 patients at baseline"
Presenter: Marie Piecyk, PhD, Researcher, Center for Innovation in Cancerology of Lyon (CICLY), Hospices Civils de Lyon, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon
Date and Time: Friday, March 28, 2025, 1:00PM – 1:45PM (CET)
The poster presentations can be viewed at
#282P
#395P